In summary, CTLA-4 inhibitors may be used to treat CRC with a combination of drugs that modulate CD80 and CD86 expression, or in combination with PD-L1 inhibitors, may achieve better therapeutic outcomes (49). Here, CTLA4 is linked to colorectal carcinoma.